Effects of D-003, a new substance purified from sugar cane wax, on platelet aggregation and plasma levels of arachidonic acid metabolites in healthy volunteers

International Journal of Clinical Pharmacology Research

Volumn 24, Issue 2-3, 2004, Pages 55-63

  Arruzazabala, M L ^a   Mas, R ^a   Molina, V ^a   Carbajal, D ^a   Fernandez L ^a   Illnait, J ^a   Castano G ^b   Fernandez J ^a   Mendoza, S ^a  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

^b Medical Surgical Research Center   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; COLLAGEN; D 003; PLACEBO; PROSTACYCLIN; THROMBOXANE B2;

ADULT; ARTICLE; CONTROLLED STUDY; FATTY ACID BLOOD LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; METABOLITE; NORMAL HUMAN; SUGARCANE; THROMBOCYTE AGGREGATION; VOLUNTEER;

ADULT; ARACHIDONIC ACIDS; ASTHENIA; COLLAGEN TYPE I; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EPOPROSTENOL; FATTY ACIDS; FEMALE; HEADACHE; HUMANS; MALE; MIDDLE AGED; PLANT EXTRACTS; PLATELET AGGREGATION; SACCHARUM; TABLETS; THROMBOXANE B2; TIME FACTORS; WAXES;

EID: 11844286310     PISSN: 02511649     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Wu K. Recent advances in hemostatic risk factors and cardiovascular diseases. Fibrinol. Proteol., 11(Suppl. 1), 3, 1997.
2. Murray C.J.L., López A.D. Alternate projections of mortality and disability by cause 1990-2020. Global Burden Disease Study. Lancet, 349, 1498, 1997.
3. Brown M.S., Goldstein J.L. Heart attacks: Gone with the century. Science, 272, 629, 1996.
4. Falk E., Fernández-Ortiz A. Role of thrombosis in atherosclerosis and its complications. Am. J. Cardiol., 75, 1, 1995.
5. Schafer A. Antiplatelet therapy. Am. J. Med., 101, 199, 1996.
6. Haller H. Endothelial function: General considerations. Drugs, 53(Suppl. 1), 1, 1997.
7. Luscher T.F. Biology of the endothelium. Clin. Cardiol., 20(Suppl. 2), 2, 1997.
8. Prediman K.S. Plaque disruption and coronary thrombosis: New insights into pathogenesis and prevention. Clin. Cardiol., 20(Suppl. 2), 2, 1997.
9. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy-I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ, 308, 81, 1994.
10. Cairns J.A., Lewis D.J., Meade T.W., et al. Antithrombotic agents in coronary artery disease. Chest, 108(Suppl. 4), 380, 1995.
11. Sherman D., Dyken M., Gent M., et al. Antithrombotic therapy for cerebrovascular disorders. An update. Chest, 108(Suppl. 4), 444, 1995.
12. EUROASPIRE Study Group. European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results. Eur. Heart J., 18, 1569, 1997.
13. Wood D. European and American recommendations for coronary heart disease prevention. Eur. Heart J., 19(Suppl. A), 12, 1998.
14. Hassan M., Amonkar M. Aspirin for primary and secondary prophylaxis of cardiovascular disease. Curr. Ther. Res., 62, 676, 2001.
15. Awiry E.H., Loscalzo J. Aspirin. Circulation, 101, 1206, 2000.
16. Patrono C., Coller B., Dalen J.E., et al. Platelet-active drugs: The relationships among dose, effectiveness, and side effects. Chest, 119, 39, 2001.
17. McTavish D., Faulds D., Goa K.L. Ticlopidine: An updated review of its pharmacology and therapeutic use in platelet-dependent disorders. Drugs, 40, 238, 1990.
18. Coukell A.J., Markham A. Clopidogrel. Drugs, 54, 745, 1997.
19. The CARRIE Study Group. A randomized, blinded trial of clopidogrel versus aspirin in patients at high risk of ischemic events (CAPRIE). Lancet, 348, 1329, 1996.
20. Coller B.S., Peerch E.I., Scudder L.E., Sullovan C.A. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thromboasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J. Clin. Invest., 72, 325, 1983.
21. Tanemoto K., Kanaoka Y., Kuinose M. Assessment of antithrombotic agents using the platelet aggregation test. Curr. Ther. Res., 61, 798, 2000.
22. González L., Marrero D., Laguna A., et al., inventors. Laboratories Dalmer SA, assignee: Mixture of primary fatty acids of high molecular weight obtained from sugar cane wax and its pharmaceutical uses Republic of South Africa patent, 98, 2744. Oecember 30, 1998.
23. Molina V., Arruzazabala M.L., Carbajal D., et al. Antiplatelet and antithrombotic effects of D-003. Pharmacol. Res., 42, 137, 2000.
24. Molina V., Arruzazabala M.L., Carbajal D., Mas R. D-003, a new compound with effects on arachidonic acid metabolites. Prostaglandins Leukot. Essent. Fatty Acids, 67, 19, 2002.
25. Gámez R., Más R., Noa M., Menéndez R., et al. Acute and subchronic oral toxicity of D-003 in rats. Toxicol. Lett., 118, 31, 2000.
26. Gámez R., González J.E., Rodeiro I., et al. In vivo genotoxic evaluation of D-003, a mixture of very long-chain aliphatic acids. J. Med. Food, 4, 85, 2001.
27. Gámez R., Rodeiro I., Fernández I., Acosta P.C. A preliminary evaluation of the cytotoxic and genotoxic potential of D-003: A mixture of very long chain fatty acids. Teratog. Carcinog. Mutagen., 22, 175, 2002.
28. Castaño G., Mas R., Fernández L., et al. Assessment of the effects of D-003, a new antiplatelet and lipid-lowering compound, in healthy volunteers. Drugs, 3, 337, 2002.
29. Arruzazabala M.L., Carbajal D., Mas R., et al. Effects of D-003, a new compound purified from sugar cane wax, on platelet aggregation in healthy volunteers: A randomized, double-blinded clinical study. Clin. Drug Invest., 23, 107, 2002.
30. Born G. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature, 194, 927, 1962.
31. Patrono C., Ciabattoi G., Pugliese F., et al. Radioimmunoassay of serum thromboxane B2: A simple method of assessing pharmacologic effects on platelet function. In: Samuelsson B., Ramwell P.W., Paoletti R. (Eds.). "Advances in Prostaglandin and Thromboxane Research." Raven Press, New York, 1980, pp. 6-187.
32. Arruzazabala M.L., Carbajal D., Más R., et al. Effects of D-003, a new compound purified from sugarcane wax, on platelet aggregation in healthy volunteers. Clin. Drug Invest., 23, 107, 2003.
33. Packham M.A. The role of platelets in thrombosis and hemostasis. Can. J. Physiol. Pharmacol., 72, 278, 1994.
34. Fitzgerald G.A., Oates J.A., Hawinger J., et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J. Clin. Invest., 71, 676, 1988.
35. Kormoczy P.S., Vertesi C., Mikus E., et al. Cardioprotective effect of Pgl2 and 7-oxo-Pgl2 in rats against chronic isoproterenol damage. Prostaglandins, 33, 505, 1987.
36. Attar A., Tuna H., Sargomn M.F., et al. Early protective effects of iloprost after experimental spinal cord injury. Neurol. Res., 20, 353, 1998.